Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours

Abstract ER/PR+HER2- breast tumours are the most predominant subtype of breast cancer worldwide, including India. Unlike TNBCs, these tumours can be treated with anti-estrogens or aromatase inhibitors. Despite the success of endocrine therapy, a fraction of patients with ER/PR+ breast tumours do not...

Full description

Saved in:
Bibliographic Details
Main Authors: Arnab Ghosh, Rohan Chaubal, Chitrarpita Das, Pallavi Parab, Subrata Das, Arindam Maitra, Partha P. Majumder, Sudeep Gupta, Nidhan K. Biswas
Format: Article
Language:English
Published: Nature Portfolio 2025-02-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-025-07606-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s42003-025-07606-x

Similar Items